SAN DIEGO, CA / ACCESSWIRE / May 20, 2015 / Innovus Pharmaceuticals, Inc., ("InnovusPharma" or the "Company") www.innovuspharma.com (OTCQB: INNV) a company focusing on the commercialization of over-the-counter ("OTC") and consumer products for men's and women's health, vitality and respiratory diseases announced today that multiple new large online distributors and catalogues have begun recently to carry and order its products in the U.S.

The new online distributors include Freedom Hill, Drugstore.com, Quest Products, Pharma Packs, and Swanson Health. Silver Star Brands is now carrying Innovus products through its catalogue business.

"We believe that our products are getting very good reception from our consumers to date and thus, are allowing us to push them through a multitude of channels in the U.S. including large online distributors and catalogues. The new list of distributors and catalogues announced today by us is the first wave of expansion as we continue to make our products available to consumers and we expect to announce additional new distributors in the near term," said Dr. Bassam Damaj, President and Chief Executive Officer of Innovus Pharma.

About Innovus Pharmaceuticals, Inc.

Headquartered in San Diego, Innovus Pharma is an emerging leader in over-the-counter ("OTC") and consumer products for men's and women's health and vitality. The Company generates revenues from its lead products Zestra(R) for female arousal and EjectDelay(R) for premature ejaculation and has a total of five marketed products in this space, including Sensum+(R) for the indication of reduced penile sensitivity, (for sales outside the U.S. only), Zestra Glide(R) Lubricant, Vesele(R) for promoting sexual and cognitive health, and Androferti(R) (in the US and Canada) to support overall male reproductive health and sperm quality and one product candidate, FlutiCare(TM) for Allergic Rhinitis, that is currently under review as an Abbreviated New Drug Application ("ANDA") by the U.S. Food and Drug Administration ("FDA") for sale as an OTC product.

For more information, go to www.innovuspharma.com, www.zestra.com; www.ejectdelay.com; www.myvesele.com; www.sensumplus.com; and www.myadroferti.com

Innovus Pharma's Forward-Looking Safe Harbor

Statements under the Private Securities Litigation Reform Act, as amended: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties that may individually or mutually impact the matters herein described for a variety of reasons that are outside the control of the Company, including, but not limited to, receiving patent protection for any of its products, receiving approval or to be compliant with the requirements of any relevant regulatory authority relating to such products, and to successfully commercialize such products in the U.S. through various distribution channels and in other countries and regions, and to achieve its other development, commercialization, financial and staffing objectives. Readers are cautioned not to place undue reliance on these forward-looking statements as actual results could differ materially from the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company's most recent annual report on Form 10-K, subsequent quarterly reports filed on Form 10-Q and other filings made with the SEC. Copies of these reports are available from the SEC's website or without charge from the Company.

Innovus Pharma Contact:

Kevin Holmes
Chesapeake Group
info@chesapeakegp.com
T: 410-825-3930

SOURCE: Innovus Pharmaceuticals, Inc.